Daito Pharmaceutical Co.,Ltd. (TYO:4577)

Daito Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is June - May.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 30, 2024	May 31, 2024	May 31, 2023	May 31, 2022	May 31, 2021	May 31, 2020
Cash & Equivalents	3,241	2,727	3,607	4,381	3,372	3,084
Cash & Short-Term Investments	3,241	2,727	3,607	4,381	3,372	3,084
Cash Growth	-29.31%	-24.40%	-17.67%	29.92%	9.34%	69.54%
Accounts Receivable	18,435	15,441	17,654	16,146	12,791	15,521
Other Receivables	48	1,292	-	-	-	-
Receivables	18,483	16,733	17,654	16,146	12,791	15,521
Inventory	21,069	20,890	18,238	16,820	15,751	12,130
Other Current Assets	808	1,110	1,164	562	515	120
Total Current Assets	43,601	41,460	40,663	37,909	32,429	30,855
Property, Plant & Equipment	31,465	31,972	25,837	23,116	21,372	19,399
Long-Term Investments	4,084	3,464	3,169	2,958	3,096	3,393
Other Intangible Assets	481	490	377	386	332	299
Long-Term Deferred Tax Assets	-	320	504	570	508	302
Other Long-Term Assets	2	2	2	-	2	1
Total Assets	79,633	77,708	70,552	64,939	57,739	54,249
Accounts Payable	9,045	8,699	8,172	7,864	7,730	8,392
Accrued Expenses	-	1,051	1,091	1,170	1,106	960
Short-Term Debt	-	-	69	11	11	64
Current Portion of Long-Term Debt	3,299	2,099	1,429	1,189	1,362	1,512
Current Portion of Leases	-	275	15	-	1	2
Current Income Taxes Payable	920	4,681	4,288	3,319	2,564	3,523
Other Current Liabilities	4,173	1,700	364	516	84	601
Total Current Liabilities	17,437	18,505	15,428	14,069	12,858	15,054
Long-Term Debt	8,019	4,669	3,368	2,247	2,018	1,581
Long-Term Leases	-	1,676	77	-	-	1
Long-Term Deferred Tax Liabilities	-	32	31	32	28	27
Other Long-Term Liabilities	1,831	242	180	165	155	151
Total Liabilities	27,614	25,444	19,581	17,268	15,823	17,382
Common Stock	7,186	7,186	7,186	7,031	6,271	5,370
Additional Paid-In Capital	7,072	7,072	7,072	6,917	6,157	5,256
Retained Earnings	36,671	37,087	35,006	32,338	28,331	24,742
Treasury Stock	-126	-990	-124	-13	-13	-13
Comprehensive Income & Other	1,209	1,713	1,532	1,031	872	1,153
Total Common Equity	52,012	52,068	50,672	47,304	41,618	36,508
Minority Interest	7	196	299	367	298	359
Shareholders' Equity	52,019	52,264	50,971	47,671	41,916	36,867
Total Liabilities & Equity	79,633	77,708	70,552	64,939	57,739	54,249
Total Debt	11,318	8,719	4,958	3,447	3,392	3,160
Net Cash (Debt)	-8,077	-5,992	-1,351	934	-20	-76
Net Cash Per Share	-523.26	-381.87	-85.36	61.01	-1.33	-5.39
Filing Date Shares Outstanding	15.29	15.29	15.8	15.85	15.08	14.8
Total Common Shares Outstanding	15.29	15.29	15.8	15.72	15.08	14.48
Working Capital	26,164	22,955	25,235	23,840	19,571	15,801
Book Value Per Share	3401.01	3404.66	3206.47	3009.74	2758.92	2520.43
Tangible Book Value	51,531	51,578	50,295	46,918	41,286	36,209
Tangible Book Value Per Share	3369.56	3372.62	3182.62	2985.18	2736.91	2499.79
Order Backlog	-	5,417	5,223	7,585	6,664	4,689

Source: S&P Capital IQ. Standard template. Financial Sources.